Validity and responsiveness of the Euro-Qol-5 Dimensions-5 Levels (EQ5D5L) in IPF

C. Nolan (London, United Kingdom), M. Maddocks (London, United Kingdom), T. Maher (London, United Kingdom), S. Jones (London, United Kingdom), S. Patel (London, United Kingdom), R. Barker (London, United Kingdom), P. George (London, United Kingdom), W. Man (London, United Kingdom)

Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias
Session: Consequences of idiopathic interstitial pneumonias
Session type: Thematic Poster
Number: 2899
Disease area: Interstitial lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Nolan (London, United Kingdom), M. Maddocks (London, United Kingdom), T. Maher (London, United Kingdom), S. Jones (London, United Kingdom), S. Patel (London, United Kingdom), R. Barker (London, United Kingdom), P. George (London, United Kingdom), W. Man (London, United Kingdom). Validity and responsiveness of the Euro-Qol-5 Dimensions-5 Levels (EQ5D5L) in IPF. 2899

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
COPD Assessment Test (CAT) has a positive relationship with exacerbations in COPD patients.
Source: International Congress 2019 – Clinical implications of COPD management
Year: 2019

Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Source: International Congress 2014 – COPD markers
Year: 2014

Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations
Source: International Congress 2015 – The immunology of allergic airway disease
Year: 2015


Assessment of the potential utility of alveolar volume (VA) as a surrogate for total lung capacity (TLC)
Source: International Congress 2014 – Respiratory function at rest and during exercise
Year: 2014


Lung Clearance Index (LCI) measurements are reproducible and associated with airway physiological changes in steroid naive asthmatic (SNA) adults
Source: International Congress 2017 – Biomarker-based asthma control
Year: 2017

The EQ5D5L in COPD: Validity, responsiveness and minimum important difference (MID)
Source: International Congress 2015 – Latest insights into pulmonary rehabilitation
Year: 2015


CT scan derived emphysema scores correlate with spirometry and gas exchange but not acute exacerbation rates (AER) or COPD assessment test (CAT) in COPD subjects with and without alpha-1-antitrypsin (AAT) deficiency
Source: Annual Congress 2013 –Monitoring lung function in airway diseases
Year: 2013


Studies on interferon-gamma (IFN-γ) expression in lower airways of patients with idiopathic pulmonary fibrosis (IPF), sarcoidosis and pneumoconioses. Lower IFN-γ levels in bronchoalveolar lavage (BAL) supernatants of IPF subgroup with decrease
Source: Eur Respir J 2007; 30: Suppl. 51, 121s
Year: 2007

The effect of posture on ventilation using structured light plethysmography (SLP) in alpha 1 anti-trypsin deficiency (A1AT)
Source: International Congress 2014 – Innovative technology and techniques in respiratory function
Year: 2014

Expression of interleukin-27 (IL27) in human lower airways. Pathophysiological implications in pulmonary sarcoidosis (PS)
Source: Annual Congress 2012 - Diffuse parenchymal lung disease I
Year: 2012

Plasma surfactant protein D (SP-D) and nutritive status in patients with COPD
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013

COPD: Acute exacerbation (AE) rate and saturation in the patients with different plasma surfactant protein D (SP-D) level
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013

Markers of inflammation and pulmonary function (PF) in sarcoidosis
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010


Comparison of individual items of COPD Assessment Test (CAT) at baseline in the EMAX and IMPACT trials
Source: Virtual Congress 2020 – New tools for diagnosis of obstructive diseases
Year: 2020


Plasma surfactant protein-D (SPD) concentration and severity of airflow limitation in COPD patients (pts)
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016

Comparison between electronic and paper versions of the Evaluating Respiratory Symptoms in COPD (E-RS) and the COPD Assessment Test (CAT).
Source: International Congress 2017 – What is new in COPD diagnosis and classification?
Year: 2017


Impulse-oscillometry (IOS) differences in asthma and COPD patients, and healthy-subjects
Source: International Congress 2014 – Airways: reversibility and responsiveness
Year: 2014


The combination of elevated FeNO and blood eosinophils relate to reduced lung function and increased bronchial responsiveness in young asthmatics
Source: International Congress 2014 – Biomarkers of asthma control
Year: 2014

Validation of nitrogen washout (N2-WO) for measurement of lung clearance index (LCI) and functional residual capacity (FRC) in preschoolers
Source: International Congress 2016 – What's new in paediatric respiratory physiology?
Year: 2016


Use of interleukin-1beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1Ra) contents in alveolar macrophages for estimation of inflammation activity in patients with different levels of asthma control
Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection
Year: 2013